The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Ohioans must recognize the threat that vertically-integrated insurance conglomerates pose to our health and pocketbooks.

The lawsuit followed a scathing FTC report in July that said the "dominant ... of Georgia's independent pharmacists and the need for PBM transparency." In his veto message, Kemp voiced support ...

Morgan Harper is the director of policy and advocacy and Emma Freer is a senior policy analyst at the American Economic Liberties Project. “I don't know what some of the (patients) are going to ...

Boston life sciences and medical device leaders agreed that the change to a Trump administration could create a more ...

Calls for PBM reform focus on transparency and addressing monopolistic practices to improve drug affordability. The FTC's action underscores the need for urgent reforms to address PBMs' anti ...

Nationally, criticism of PBM practices intensified over the summer with the FTC report. The PCMA pushed back, saying the ...

FTC Chairwoman Lina Khan, with her fellow Democratic Commissioners, recently filed a suit against the leading PBMs in an effort to undermine, or even prohibit, their use of rebates to secure ...

This was days after Express Scripts started the legal volleying with a federal lawsuit against the FTC, which accused the agency of making false and misleading claims about the PBM industry in a ...